Progyny, Inc. SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense
Progyny, Inc. (PGNY) reported SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense of $5.56 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Notes › Valuation and Qualifying Accounts
us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense · last filed 2021-03-01
- Progyny, Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for the quarter ending 2020-12-31 was $1.85M, a 573.82% increase year-over-year.
- Progyny, Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for the quarter ending 2020-09-30 was $1.24M.
- Progyny, Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for the quarter ending 2020-06-30 was $1.21M.
- Progyny, Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for the quarter ending 2020-03-31 was $1.26M.
- Progyny, Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2020 was $5.56M, a 246.33% increase from fiscal 2019.
- Progyny, Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2019 was $1.61M, a 94.90% increase from fiscal 2018.
- Progyny, Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2018 was $824.00K.
| Period end | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 3 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 6 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 9 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 12 month |
|---|---|---|---|---|
| 2020-12-31 | $1.85M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $3.09M derived: sum of 2 quarters · filed 2021-03-01 | $4.30M derived: sum of 3 quarters · filed 2021-03-01 | $5.56M 10-K · filed 2021-03-01 |
| 2020-09-30 | $1.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $2.45M derived: sum of 2 quarters · filed 2020-11-06 | $3.71M 10-Q · filed 2020-11-06 | $3.98M derived: sum of 4 quarters · filed 2021-03-01 |
| 2020-06-30 | $1.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $2.47M 10-Q · filed 2020-08-07 | $2.74M derived: sum of 3 quarters · filed 2021-03-01 | |
| 2020-03-31 | $1.26M 10-Q · filed 2020-05-14 | $1.53M derived: sum of 2 quarters · filed 2021-03-01 | ||
| 2019-12-31 | $275.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $1.61M 10-K · filed 2021-03-01 | ||
| 2019-09-30 | $1.33M 10-Q · filed 2019-12-06 | |||
| 2018-12-31 | $824.00K 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |